Republicans are searching for a candidate who can unite the party’s pro-business establishment with its small-government activists. Pence’s allies say the temperate-toned governor has a record that pleases both.
Texas Monthly, the award-winning magazine owned by Indianapolis-based Emmis Communications Corp., says the Times hired away its top editor to join the newspaper’s magazine division before his contract expired.
Former hedge-fund executives who left Wall Street are finding new ways to milk profits from old trailer parks, including one in Indianapolis.
WellPoint Inc. is leading companies that have poured $13.4 million into defeating a ballot initiative that would give California regulators the power to reject increases in health policy premiums.
California, the U.S. state with the largest population and budget, offers the least website access to its government spending data, according to a new study. Indiana provided the most information.
Takeda Pharmaceutical Co. and Eli Lilly and Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
Pfizer Inc., Eli Lilly and Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential.
Kentucky’s coaching staff will reap an extra $736,000 if the team wins the NCAA basketball tournament. Meanwhile, players are being asked by security to remove labels from water bottles at practice to avoid conflicts with a sponsorship agreement.
“Troll” is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.’s first marketed product. The treatment would compete against Lilly’s Humalog. An FDA report tied the drug to a decline in lung function.
Lawsuits challenging amateurism in U.S. college sports may result in higher costs for universities and the National Collegiate Athletic Association, Moody’s Investors Service said Thursday.
In a stunning ruling that could revolutionize a college sports industry worth billions of dollars and have dramatic repercussions for the Indianapolis-based NCAA, a federal agency said Wednesday that players at Northwestern can unionize.
Simon Property Group told a Delaware judge on Tuesday that an investor lawsuit over David Simon’s huge pay package should be thrown out now that the company has rewritten the compensation plan.
Two months before health insurers must submit rate proposals for 2015 to government regulators, WellPoint Inc. fired a surprising shot across their bow.
U.S. Steel and Steel Dynamics Inc., which have thousands of employees in Indiana, are among steel companies who say they have been unfairly harmed as imports of the products are sold more cheaply than domestic producers can make them.
The mayor of Connersville declared a financial emergency three months into budget year.The culprit is the loss of a single employer, Visteon Corp., which closed an auto-parts plant in 2008, throwing 900 people out of work.
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
